Clofibrate increases lipoprotein-lipase activity in adipose tissue of hypertriglyceridaemic patients.
Clearance of plasma-triglycerides and activity of lipoprotein lipase in adipose tissue were studied in six hypertriglyceridaemic patients before and after a week of clofibrate therapy (2 g/day). Plasma-triglycerides decreased significantly from 6.85 +/- 1.1 to 2.66 +/- 0.29 mmol/l and triglyceride clearance increased significantly from 1.3 +/- 0.2 to 2.4 +/- 0.4%/min. There were concomitant significant increases in heparin-releasable lipoprotein lipase (95 +/- 16 to 181 +/- 34 nmol free fatty acids/10(6) cells/h) and in extractable lipase (88 +/- 14 to 179 +/- 28 nmol free fatty acids/10(6) cells/h). It is concluded that an important effect of clofibrate may be to increase the levels of adipose-tissue lipoprotein lipase and thereby improve the clearance of plasma-triglycerides.
D000273:Adipose Tissue / Q000201:enzymology*; D000328:Adult; D002994:Clofibrate / Q000627:therapeutic use*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D066298:In Vitro Techniques; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D013268:Stimulation, Chemical; D014280:Triglycerides / Q000097:blood*
D014280:Triglycerides; D006493:Heparin; D008071:Lipoprotein Lipase; D002994:Clofibrate